BioInformant

Your Global Leader in Stem Cell Market Research

Home » bioinformant » Page 9

Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study

By Leave a Comment

The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of XSTEM. Xintela has previously communicated positive interim results up to 18 months after treatment of knee osteoarthritis patients with three dose levels of XSTEM. The highest dose level, which showed the best results after 18 months, has now shown sustained positive treatment effects two years after XSTEM treatment.
XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. [Read more…]

Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo

By Leave a Comment

Join us in College Park on October 21 during the lunch keynote session

COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo. The premier event will take place at The Hotel at the University of Maryland on October 21, 2025. Gov. Moore will be making a special appearance during the lunch keynote session. [Read more…]

The Global Stem Cell Market and What It Means for Students Considering STEM Careers

By Leave a Comment

As the field of medical research accelerates, stem cell technology stands at the forefront of innovative treatment options and scientific discovery. The global stem cell market is projected to surpass significant financial milestones, making it a hot topic in both the scientific community and the business world. For students contemplating careers in science, technology, engineering, and mathematics (STEM), this growing market offers both exciting possibilities and serious considerations as they shape their educational paths. [Read more…]

Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF

By Leave a Comment

SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.

Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0